DR. REDDY'S LABORATORIES-ADR (RDY) Stock News
NYSE:RDY - New York Stock Exchange, Inc. - US2561352038 - ADR - Currency: USD
RDY Latest News, Press Relases and Analysis
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering
DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong earnings growth, low debt, and solid profitability, making it a candidate for GARP investors. Read why it fits the Peter Lynch strategy.
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Dr. Reddy’s Q4 & Full Year FY25 Financial Results
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes
Despite the impact of dynamic shifts in the regulatory landscape for the Zacks Medical - Generic Drugs industry, new product launches should provide some respite to RDY, SDZNY and TEVA.
Mentions: TEVA
Dr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires
We recently published a list of the 10 Best Indian Stocks to Buy According to Billionaires. In this article, we will take a look at where Dr. Reddy’s Laboratories Limited (NYSE:RDY) stands against other best Indian stocks. India’s stock market had a rough ride during the second half of FY25, amid uncertainty around US tariffs, […]
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
/PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and...
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Mentions: ALVO
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
Henlius und Dr. Reddy's unterzeichnen Lizenzvertrag für HLX15 (Daratumumab-Biosimilar) zur Expansion in Europa und den USA
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) meldete heute die Unterzeichnung einer Lizenzvereinbarung mit Dr. Reddy's Laboratories SA, einer...
Henlius y Dr. Reddy's firman un acuerdo de licencia para la expansión de HLX15 en Europa y EE.UU.
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) anunció hoy que ha firmado un acuerdo de licencia con Dr. Reddy's Laboratories SA, filial de propiedad...
Henlius et Dr. Reddy's signent un accord de licence pour l'expansion de HLX15 (biosimilaire expérimental du daratumumab) en Europe et aux États-Unis.
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) a annoncé aujourd'hui qu'elle avait conclu un accord de licence avec Dr. Reddy's Laboratories SA,...
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned...
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.
Mentions: HLN
Dr. Reddy’s Q3 & 9MFY25 Financial Results
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
Dr. Reddy’s Q2 & H1FY25 Financial Results
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.
Mentions: COLL
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
